5.83  0.04 (0.69%)		07-26 16:00
Open: 5.93 High: 5.96 Volume: 185,347		Pre. Close: 5.79 Low: 5.7 Market Cap: 361(M)

Short term
Mid term
Targets	6-month :	6.96	1-year :	8.13
Resists	First :	5.96	Second :	6.96
Pivot price	5.34
Supports	First :	4.94	Second :	4.32
MAs	MA(5) :	5.7	MA(20) :	5.12
	MA(100) :	5.14	MA(250) :	4.68
MACD	MACD :	0.2	Signal :	0.2
%K %D	K(14,3) :	89.7	D(3) :	88.4
RSI	RSI(14): 71
52-week	High :	7.79	Low :	2.68

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ INZY ] has closed below upper band by 22.0%. Bollinger Bands are 27.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.96 - 5.98	5.98 - 6
Low:	5.65 - 5.67	5.67 - 5.69
Close:	5.79 - 5.82	5.82 - 5.86

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Mon, 15 Jul 2024
Inozyme Pharma, Inc. (NASDAQ:INZY) Sees Large Growth in Short Interest - American Banking and Market News

Sat, 29 Jun 2024
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts? - Yahoo Finance

Fri, 03 May 2024
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Tue, 26 Mar 2024
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 - Yahoo Finance

Tue, 12 Mar 2024
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights - Yahoo Finance

Fri, 08 Mar 2024
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward (INZY) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	62 (M)
Shares Float	38 (M)
Held by Insiders	0.5 (%)
Held by Institutions	92.7 (%)
Shares Short	4,130 (K)
Shares Short P.Month	2,720 (K)

EPS	-1.36
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.91
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.6 %
Return on Equity (ttm)	-69.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.33
Qtrly Earnings Growth	0 %
Operating Cash Flow	-77 (M)
Levered Free Cash Flow	-53 (M)

PE Ratio	-4.32
PEG Ratio	-0.3
Price to Book value	3.03
Price to Sales	0
Price to Cash Flow	-4.66

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.